VIATRIS INC. (VTRS) Debt Components
- 2026-06-30: Long-term Debt, Current MaturitiesUSD $1.74B; Debt, CurrentUSD $1.74B; Long-term Debt, Excluding Current MaturitiesUSD $11.61B; Long-Term Debt, Maturity, Year OneUSD (m).
- 2026-03-31: Long-term Debt, Current MaturitiesUSD $1.93B; Debt, CurrentUSD $1.93B; Long-term Debt, Excluding Current MaturitiesUSD $12.41B; Long-Term Debt, Maturity, Year OneUSD (m).
- 2025-12-31: Long-term Debt, Current MaturitiesUSD $1.93B; Debt, CurrentUSD $1.93B; Long-term Debt, Excluding Current MaturitiesUSD $12.48B; Long-Term Debt, Maturity, Year OneUSD $0.00.
- 2025-09-30: Long-term Debt, Current MaturitiesUSD $1.95B; Debt, CurrentUSD $1.94B; Long-term Debt, Excluding Current MaturitiesUSD $12.49B; Long-Term Debt, Maturity, Year OneUSD (m).
VIATRIS INC. Debt Components
Filed components and totals, with each concept and unit kept separate. Components can overlap; they are not added together. Missing disclosures remain (m). Original concept pages retain their detailed breakdowns and history.
| Period end | Long-term Debt, Current Maturities USD | Debt, Current USD | Long-term Debt, Excluding Current Maturities USD | Long-Term Debt, Maturity, Year One USD | Long-Term Debt, Maturity, Year Two USD | Long-Term Debt, Maturity, Year Three USD | Long-Term Debt, Maturity, Year Four USD | Long-Term Debt, Maturity, Year Five USD | Long-Term Debt, Maturity, after Year Five USD | Long-term Debt, Gross USD | Short-term Debt USD | Long-term Debt USD | Line of Credit Facility, Maximum Borrowing Capacity USD | Line of Credit Facility, Capacity Available for Specific Purpose Other than for Trade Purchases USD | Debt Instrument, Face Amount USD | Debt Instrument, Unamortized Discount USD | Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net USD |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $1.74B | $1.74B | $11.61B | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2026-03-31 | $1.93B | $1.93B | $12.41B | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2025-12-31 | $1.93B | $1.93B | $12.48B | $0.00 | $1.72B | $1.61B | $246.00M | $1.45B | $7.92B | $12.94B | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2025-09-30 | $1.95B | $1.94B | $12.49B | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2025-06-30 | $1.68B | $1.67B | $12.79B | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2025-03-31 | $8.50M | $700.00K | $14.18B | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-12-31 | $8.30M | $600.00K | $14.04B | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-12-31 | (m) | (m) | (m) | $0.00 | $1.95B | $1.75B | $1.63B | $0.00 | $8.67B | $13.99B | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-09-30 | $1.45B | $1.44B | $14.30B | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-06-30 | $2.37B | $2.36B | $14.73B | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-03-31 | $1.90B | $1.89B | $16.07B | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-12-31 | $1.94B | $1.93B | $16.19B | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-12-31 | (m) | (m) | (m) | $1.11B | $325.00M | $1.95B | $1.70B | $1.58B | $8.59B | $15.27B | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-09-30 | $1.31B | $1.30B | $17.08B | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $100.00K | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-06-30 | $1.33B | $1.33B | $17.25B | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $23.20M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-03-31 | $508.70M | $500.10M | $18.07B | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $204.60M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2022-12-31 | $1.26B | $1.25B | $18.02B | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2022-12-31 | (m) | (m) | (m) | $500.00M | $1.85B | $1.28B | $2.52B | $1.65B | $10.06B | $17.86B | $0.00 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2022-09-30 | $763.80M | $755.00M | $18.72B | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $500.40M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2022-06-30 | $768.20M | $758.60M | $19.21B | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $1.02B | (m) | (m) | (m) | (m) | (m) | (m) |
| 2022-03-31 | $2.61B | $2.60B | $18.76B | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $655.40M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-12-31 | $1.88B | $1.86B | $19.72B | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $1.49B | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-12-31 | (m) | (m) | (m) | $0.00 | $1.25B | $1.72B | $1.24B | $3.23B | $11.49B | $18.92B | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-09-30 | $1.91B | $1.88B | $19.85B | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $1.71B | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-06-30 | $2.18B | $2.15B | $20.92B | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $1.30B | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-03-31 | $2.30B | $2.26B | $22.10B | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $36.90M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-12-31 | $2.31B | $2.26B | $22.43B | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $1.10B | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-12-31 | (m) | (m) | (m) | $0.00 | $1.87B | $1.25B | $2.03B | $1.33B | $14.61B | $21.09B | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-09-27 | (m) | (m) | $11.54B | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $11.54B | (m) | (m) | $11.64B | $15.00M | $-103.00M |
| 2020-06-28 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $4.00B | $1.50B | (m) | (m) | (m) |
| 2020-06-28 | (m) | (m) | $11.39B | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $11.39B | (m) | (m) | $11.49B | $15.30M | $-104.30M |
| 2019-12-31 | $1.51B | $1.46B | $11.21B | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $0.00 | (m) | (m) | (m) | (m) | (m) | (m) |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |